At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 228 enrolled
Drug / intervention
Atomoxetinedrug
Likely dose
Atomoxetine 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride
In Brief
A Phase 4 clinical trial evaluating Atomoxetine for Attention Deficit Hyperactivity Disorder. Completed, enrolled 228 participants across 8 sites in 3 countries.
Detailed Summary
The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children treated with atomoxetine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesChina, South Korea, Taiwan
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2007
Primary CompletionNov 2008
TodayJul 2026
First PostedMay 9, 2007
Enrollment StartApr 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.1 years ago
Interventions
Atomoxetinedrug
atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.